Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP19 | O94966 | 2/20 | 0.37 |
| ▸ | USP5 | P45974 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909480 | 1.00 | USP19 (0.37) | USP19USP5TSHRUSP7AKT1 | |
| SCHEMBL23909478 | 1.00 | USP19 (0.37) | USP19USP5TSHRUSP7AKT1 | |
| SCHEMBL23909450 | 0.99 | USP19 (0.39) | USP19USP5TSHRUSP7AKT1 | |
| SCHEMBL23909449 | 0.99 | USP19 (0.39) | USP19USP5TSHRUSP7AKT1 | |
| SCHEMBL23909504 | 0.88 | USP5 (0.36) | USP19USP5TSHRUSP7PDE4A | |
| SCHEMBL23909503 | 0.88 | USP5 (0.36) | USP19USP5TSHRUSP7PDE4A | |
| SCHEMBL23924911 | 0.88 | MYC (0.33) | USP19USP5TSHRUSP7KMT2A | |
| SCHEMBL23924908 | 0.88 | MYC (0.33) | USP19USP5TSHRUSP7KMT2A | |
| SCHEMBL23909466 | 0.84 | USP5 (0.40) | USP19USP5TSHRUSP7KMT2A | |
| SCHEMBL23909506 | 0.84 | USP5 (0.40) | USP19USP5TSHRUSP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398134-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-05-02 | — | — | US | disclosed |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3802536-B1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210317116-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317116-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, CCL5 | USP19 4375/4885USP5 3028/4885TSHR 2738/4885 |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | USP19 4375/4885USP5 3028/4885TSHR 2738/4885 |
| US-12398134-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | USP19 4686/4885USP5 3372/4885TSHR 2631/4885 |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, CCL5 | USP19 4686/4885USP5 3372/4885TSHR 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.